Vetenskapliga publikationer
2024
The impact of COVID-19 on aflibercept treatment of neovascular AMD in Sweden – data from the Swedish Macula Register
Isac Wickman 1, Monica Lövestam-Adrian 2 3, Elisabet Granstam 4 5, Ulrika Kjellström 2 3, Marion Schroeder 2 3. Observational Study. BMC Ophthalmol. 2024 Jan 30;24(1):49. doi: 10.1186/s12886-024-03326-8. PMID: 38291368
Klicka här för att komma till den fullständiga publikationen.
2023
Cataract surgery in neovascular AMD: impact on visual acuity and disease activity
Hin Tan Tang, Mats Rosén, Elisabet Granstam.
2022
What about the fellow eye in treatment of neovascular age-related macular degeneration? Analysis of data from the Swedish macula register
Lövestam Adrian M, Schroeder M, Westborg I. Acta Ophthalmol. 2022 Jan 22. doi: 10.1111/aos.15094. Online ahead of print. PMID: 35064747
2021
Exploration of real-world outcomes and treatment patterns in patients treated with anti-vascular endothelial growth factors for neovascular age-related macular degeneration in Sweden
Schroeder M, Westborg I, Fluur C, Olsen R, Lövestam-Adrian M.Acta Ophthalmol. 2021 Sep 20. doi: 10.1111/aos.15025. Online ahead of print.PMID: 34543528
Risk model for intraoperative complication during cataract surgery based on data from 900 000 eyes: previous intravitreal injection is a risk factor
Hård Af Segerstad P. Br J Ophthalmol. 2021 Apr 22:bjophthalmol-2020-318645. doi: 10.1136/bjophthalmol-2020-318645
Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting
Granstam E, Aurell S, Sjövall K, Paul A. Graefes Arch Clin Exp Ophthalmol. 2021 Aug;259(8):2085-2093
2020
Treatment of age-related macular degeneration after cataract surgery: a study from the Swedish National Cataract and Macula Registers
Westborg I, Albrecht S, Granstam E, Karlsson N, Kugelberg M, Lundström M, Montan P, Behndig A. Acta Ophthalmol. 2020 Jun 23
Klicka här för att komma till den fullständiga publikationen.
2019
Twelve per cent of 6142 eyes treated for neovascular age-related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR)
Schroeder M, Westborg I, Lövestam Adrian M.Acta Ophthalmol. 2020 May;98(3):274-278. doi: 10.1111/aos.14239. Epub 2019 Sep 13.PMID: 31517440
Klicka här för att komma till den fullständiga publikationen.
2018
Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register
Lövestam Adrian M, Vassilev ZP, Westborg I.Acta Ophthalmol. 2019 Feb;97(1):91-98. doi: 10.1111/aos.13864. Epub 2018 Sep 2
Klicka här för att komma till den fullständiga publikationen.
Risk Factors for Discontinuation of Treatment for Neovascular Age-Related Macular Degeneration
Westborg I, Rosso A.Ophthalmic Epidemiol. 2018 Apr;25(2):176-182
Klicka här för att komma till den fullständiga publikationen.
2017
Risk for having low visual acuity after 1 and 2 years of treatment with ranibizumab or bevacizumab for patients with neovascular age-related macular degeneration
Westborg I, Albrecht S, Rosso A.Retina. 2017 Nov;37(11):2035-2046
Klicka här för att komma till den fullständiga publikationen.
Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register
Westborg I, Granstam E, Rosso A, Albrecht S, Karlsson N, Lövestam-Adrian M.Acta Ophthalmol. 2017 Dec;95(8):787-795.
Klicka här för att komma till den fullständiga publikationen.
2016
Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration
Rodrigues IA, Sprinkhuizen SM, Barthelmes D, Blumenkranz M, Cheung G, Haller J, Johnston R, Kim R, Klaver C, McKibbin M, Ngah NF, Pershing S, Shankar D, Tamura H, Tufail A, Weng CY, Westborg I, Yelf C, Yoshimura N, Gillies MC. Am J Ophthalmol. 2016 Aug;168:1-12. doi: 10.1016/j.ajo.2016.04.012.
Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration – a population- and register-based study from northern Sweden
Granstam E, Westborg I, Barkander A, Börjesson M, Lindahl S, Meszaros E, Wojciechowska-Zajac A, Wagner P, Albrecht S, Karlsson N, Bjärnhall G, Lövestam-Adrian M.Acta Ophthalmol. 2016 Nov;94(7):646-651
Klicka här för att komma till den fullständiga publikationen.
Utveckling av syn och behov av synrehabilitering för patienter med våt makuladegeneration efter 1- och 2-års behandling med anti-VEGF-injektioner: analyser från Svenska Makularegistret
Aldana Rosso och styrgruppen Svenska Makularegistret. Submitted 2016.
Senast uppdaterad: 12 september 2024
